|
1
|
Liu Q: Current advances in
N6-methyladenosine methylation modification during bladder cancer.
Front Genet. 12(825109)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Inamura K: Bladder cancer: New insights
into its molecular pathology. Cancers (Basel).
10(100)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Becerra-Díaz M, Valderrama-Carvajal H and
Terrazas LI: Signal transducers and activators of transcription
(STAT) family members in helminth infections. Int J Biol Sci.
7:1371–1381. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Verhoeven Y, Tilborghs S, Jacobs J, De
Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB,
Wouters A, et al: The potential and controversy of targeting STAT
family members in cancer. Semin Cancer Biol. 60:41–56.
2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Alunno A, Padjen I, Fanouriakis A and
Boumpas DT: Pathogenic and therapeutic relevance of JAK/STAT
signaling in systemic lupus erythematosus: Integration of distinct
inflammatory pathways and the prospect of their inhibition with an
oral agent. Cells. 8(898)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kitamura H, Ohno Y, Toyoshima Y, Ohtake J,
Homma S, Kawamura H, Takahashi N and Taketomi A: Interleukin-6/STAT
3 signaling as a promising target to improve the efficacy of cancer
immunotherapy. Cancer Sci. 108:1947–1952. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chen CL, Cen L, Kohout J, Hutzen B, Chan
C, Hsieh FC, Loy A, Huang V, Cheng G and Lin J: Signal transducer
and activator of transcription 3 activation is associated with
bladder cancer cell growth and survival. Mol Cancer.
7(78)2008.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Meissl K, Macho-Maschler S, Müller M and
Strobl B: The good and the bad faces of STAT1 in solid tumours.
Cytokine. 89:12–20. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Pensa sara, Regis G, Boselli D, Novelli F
and Poli V: STAT1 and STAT3 in tumorigenesis: Two sides of the same
coin? In: Madame Curie Bioscience Database. Landes Bioscience,
Austin, TX, 2013.
|
|
10
|
Wubetu GY, Utsunomiya T, Ishikawa D,
Yamada S, Ikemoto T, Morine Y, Iwahashi S, Saito Y, Arakawa Y and
Imura S: , et al: High STAT4 expression is a better
prognostic indicator in patients with hepatocellular carcinoma
After Hepatectomy. Ann Surg Oncol. 21 (Suppl 4):S721–S728.
2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhou X, Xia Y, Su J and Zhang G:
Down-regulation of miR-141 induced by helicobacter pylori promotes
the invasion of gastric cancer by targeting STAT4. Cell Physiol
Biochem. 33:1003–1012. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cheng JM, Yao MR, Zhu Q, Wu XY, Zhou J,
Tan WL and Zhan SH: Silencing of stat4 gene inhibits cell
proliferation and invasion of colorectal cancer cells. J Biol Regul
Homeost Agents. 29:85–92. 2015.PubMed/NCBI
|
|
13
|
Zhao L, Ji G, Le X, Luo Z, Wang C, Feng M,
Xu L, Zhang Y, Lau WB, Lau B, et al: An integrated analysis
identifies STAT4 as a key regulator of ovarian cancer metastasis.
Oncogene. 36:3384–3396. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Anderson K, Ryan N, Volpedo G, Varikuti S,
Satoskar AR and Oghumu S: Immune suppression mediated by STAT4
deficiency promotes lymphatic metastasis in HNSCC. Front Immunol.
10(3095)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hedl M, Sun R and Abraham C: Disease
risk-associated genetic variants in STAT1 and STAT4 function in a
complementary manner to increase pattern-recognition
receptor-induced outcomes in human macrophages. J Immunol.
205:1406–1418. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vanoni G, Ercolano G, Candiani S,
Rutigliani M, Lanata M, Derré L, Marcenaro E, Schneider P, Romero
P, Jandus C and Trabanelli S: Human primed ILCPs support
endothelial activation through NF-κB signaling. ELife.
10(e58838)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000.PubMed/NCBI View Article : Google Scholar
|
|
19
|
El Ahanidi H, El Azzouzi M, Hafidi Alaoui
C, Tetou M, Bensaid M, Chaoui I, Benbacer L, Hassan I, Oukabli M,
Michaud K, et al: Immune checkpoint and telomerase crosstalk is
mediated by miRNA-138 in bladder cancer. Front Oncol.
11(795242)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
El Azzouzi M, El Ahanidi H, Hassan I,
Tetou M, Ameur A, Bensaid M, Al Bouzidi A, Oukabli M, Alaoui CH,
Addoum B, et al: Comprehensive behavioural assessment of TERT in
bladder cancer. Urol Oncol. 42:451.e19–451.e29. 2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang Q: STAT1 as a potential therapeutic
target to treat bladder cancer. Int J Clin Exp Pathol. 17:298–307.
2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gao B, Li X, Li S, Wang S, Wu J and Li J:
Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic
marker. Phenomics. 2:33–49. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hashmi AA, Hussain ZF, Irfan M, Khan EY,
Faridi N, Naqvi H, Khan A and Edhi MM: Prognostic significance of
epidermal growth factor receptor (EGFR) over expression in
urothelial carcinoma of urinary bladder. BMC Urol.
18(59)2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hu Y, Dong Z and Liu K: Unraveling the
complexity of STAT3 in cancer: molecular understanding and drug
discovery. J Exp Clin Cancer Res. 43(23)2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang C, Xu X, Wang T, Lu Y, Lu Z, Wang T
and Pan Z: Clinical performance and utility of a noninvasive
urine-based methylation biomarker: TWIST1/Vimentin to detect
urothelial carcinoma of the bladder. Sci Rep.
14(7941)2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang J, Wang F, Liu F and Xu G:
Predicting STAT1 as a prognostic marker in patients with solid
cancer. Ther Adv Med Oncol. 12(1758835920917558)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yang C, Mai H, Peng J, Zhou B, Hou J and
Jiang D: STAT4: an immunoregulator contributing to diverse human
diseases. Int J Biol Sci. 16:1575–1585. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Litvinov IV, Cordeiro B, Fredholm S, Ødum
N, Zargham H, Huang Y, Zhou Y, Pehr K, Kupper TS, Woetmann A and
Sasseville D: Analysis of STAT4 expression in cutaneous T-cell
lymphoma (CTCL) patients and patient-derived cell lines. Cell
Cycle. 13:2975–2982. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Zhou M, Zhang P, Da M, Yang R, Ma Y, Zhao
J, Ma T, Xia J, Shen G, Chen Y and Chen D: A pan-cancer analysis of
the expression of STAT family genes in tumors and their
relationship to the tumor microenvironment. Front Oncol.
12(925537)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li C, Zhao J, Kang B, Li S, Tang J, Dong D
and Chen Y: Identification and validation of STAT4 as a prognostic
biomarker in acute myeloid leukemia. Biosci Rep.
44(BSR20231720)2024.PubMed/NCBI View Article : Google Scholar
|
